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BACKGROUND: A major objective of the IFCC Task Force on implementation of HbA1c standardization is to develop a model to define quality targets for HbA1c. 

METHODS: Two generic models, the Biological Variation and Sigma-metrics model, are investigated. Variables in the models are filled for HbA1c and data of EQA/PT programs are used to evaluate the suitability of the models to set and evaluate quality targets within and between laboratories. 

RESULTS: In the biological variation model 48% of individual laboratories and none of the 26 instrument groups met the minimum performance criterion. In the Sigma-metrics model, with a total allowable error (TAE) set at 5 mmol/mol (0.46% NGSP) 77% of the individual laboratories and 12 of 26 instrument groups met the 2 sigma criterion.





A major objective of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on Implementation of HbA1c Standardization (TF- HbA1c) is to “Develop quality targets for the measurement of HbA1c,  and on the basis of these targets, and in conjunction with professional bodies, advise on the use of HbA1c for monitoring, diagnosis and screening of diabetes and glucose intolerance” (1). This paper addresses the development of a model to set and evaluate quality targets. A suitable model should be applicable both within and between laboratories. The IFCC is an international organization that advises on quality targets and therefore the model should be generic and give local regulatory bodies the option to fill specific criteria related to e.g. financial and technical resources.   
Table 1 summarizes the key elements considered in the development of the models.  A quality target consists of a value assigned by an approved reference measurement procedure, with tolerance limits derived from the quality concept of Total Allowable Error (TAE) (2). In this concept Total Error (TE) is derived from bias and imprecision and compared with the TAE to reveal a pass or fail. The suitability of two TAE based analytical-mathematical models is investigated here: the “Biological Variation” model (BV) (3,4) and the “Sigma-metrics” model (SM) (5). To set quality targets both models require alignment with the Stockholm Hierarchy for analytical quality (6) to define TAE. In this hierarchy there are five levels: a) clinical outcomes in specific clinical settings, b) data derived from biological variation, c) published professional recommendations, d) performance goals set by regulatory bodies or organizers of External Quality Assessment (EQA) schemes, and e) current state of the art. For the SM model all levels can be used, whereas only level b applies to the BV model. Both models have a grading system to categorize the risk of not achieving the set TAE. In the SM model the risk is expressed in sigma (σ) units (the lower σ, the higher the risk of not achieving the set TAE) (5). The BV model has three categories, namely the optimum, desirable and minimum level of performance (3,4).
Several considerations may have an impact on the specifically defined criteria within both generic models: the aim of the test (e.g. diagnosis versus monitoring), test environment (e.g. Central Lab versus POCT), technical limitations (what is the state of the art), economic limitations (what cost is economically affordable), practical considerations (workload and availability of  bias and imprecision data), and clinical needs (4). 





The outcome of the BV model varies with HbA1c concentration (8) and necessitates the choice of one HbA1c concentration for evaluation. 50 mmol/mol (6.7%) is selected as most relevant as this concentration is close to and in-between the clinical decision limits for diagnosis of diabetes (48 mmol/mol; 6.5%) and a common target for treatment (53 mmol/mol; 7.0%) (9). TE and TAE are calculated with equations 1 and  2 in Table 2. Intra- and inter-individual biological variation is taken from the table published by Ricos (10). TAE is expressed in relative and absolute units .  Fig. 1A is the graphical representation of the limits for minimum, desirable and optimum performance. There are two extreme options to achieve an adequate performance level: a perfect bias with a relatively poor imprecision or a perfect imprecision with a relatively poor bias. As an example, the performance of a laboratory with a bias of 1.0 mmol/mol (0.09%) and an imprecision of 1.5% (1.0%) resulting in a TE of 2.5 mmol/mol (0.23%) is drawn in the figure. This lab meets the BV criterion for minimum performance but fails the desirable and optimum criteria. 

Sigma-metrics Model









Data from the College of American Pathologists (CAP) Survey 2014 GH2-A are used to evaluate the between laboratory performance using each model. Sample GH2-01 had an HbA1c concentration of 48 mmol/mol (6.49%) and was measured by 3277 laboratories, about 90% of them in the US. The overall and manufacturer/instrument specific bias and between laboratory CV are taken from the NGSP website (18) to calculate TE and σ (Table 1, supplemental data). In Fig. 2 bias and CV are plotted in the combined BV-SM model. To visualize positive and negative bias the figure can be expanded (Fig. 1 supplemental data). The overall mean (black star) is well outside the minimum performance criterion (amber colored) of the BV model and also not within the 2-sigma limit of the SM model. The mean performance of users within each of the respective manufacturer/instrument combinations is highly variable. The majority of the HPLC instruments do, and the majority of immunochemical and POCT instruments do not meet the 2 sigma criterion of the SM model. Only one method (N) achieves the minimum performance level of the BV model. Fig. 2 also indicates the source of poor performance: high imprecision for methods A and C, high bias for methods V and W, high bias and imprecision for methods S and O. The high bias of HPLC instruments V and W is remarkable in relation to their excellent precision. The model allows historical evaluation of this phenomenon as is shown in the supplemental data Fig. 2 and Table 2. CAP data for these instruments, dating back to 2006, are evaluated. Imprecision is relatively constant but in the early years 2006-2008 (Fig. 2, blue circles) bias was low with a performance within the 2σ limits of the SM model. 

Evaluation within laboratories






An advantage of the BV model is that once inter- and intra-individual variation are established, quality targets are fixed. But at present these parameters are not irrefutable: as stated before different values are found by different authors (10, 12, 13, 14). One publication even shows different values with different analytical methods (15). The ultimate importance of reliable data on biological variation and their impact on confidence intervals in general is described by many authors (16,17). Furthermore it is questionable whether the exact intra-individual variation can be established, because the value is in the same order of magnitude as the analytical CV of even the best methods. It is also unknown whether (narrow) biological variation data of a young, healthy, Caucasian population are applicable to other (elderly, type 1 or type 2 diabetes, well/poor controlled, ethnic) populations. A practical point of consideration is that the state of the art is quite far away from even the minimum criterion of the BV model.
A disadvantage of the SM model is that it can lead to endless discussions, without decisions, on setting an appropriate TAE and the subsequent risk to fail the set TAE (sigma). But this can also be an advantage: criteria are flexible and can be adjusted to the application (monitoring versus diagnosis), test environment (developed versus developing countries), state of the art and quality/cost issues (see considerations table 1). Another advantage is that the criteria are of the highest level of the Stockholm Hierarchy Consensus (6). This criterion is clinically and not analytically/statiscally driven and may therefore be more appealing –and thus acceptable for physicians. In developing the most appropriate quality criteria the combined model (Fig.1C) can be used but in daily practice a double target may be confusing. Balancing pros and cons, the TF- HbA1c suggests that Sigma-metrics is the model of choice.

Criteria
The goal of this paper is to define a generic model to set and evaluate quality targets. Example criteria have been used to evaluate the suitability of each of the models. The TF- HbA1c will seek collaboration with professional bodies to advocate the model and discuss/refine the most appropriate TAE and risk criteria for monitoring, diagnosis and screening of diabetes and glucose intolerance. This could be done within the framework of the Consensus Statement of HbA1c of the IDF, EASD, ADA and IFCC (7). A statement on quality targets can be added, and, like the other statements, be periodically reviewed, revised and published in diabetes related media.
Exploration of the most suitable criteria is useful as a starting point for discussion. The clinical decision limit for diagnosis (48 mmol/mol or 6.5%) is close to the upper limit of the non-diabetic reference range (42 mmol/mol or 6.0%) (9,12). Thus a small difference in HbA1c performance will have a large impact on interpretation. For example, an increase of the imprecision from 2.7 to 3.7% (1.8% to 2.5% in NGSP Units) results in a 90% increase in the prevalence of diagnosed diabetes (21). A report of the Danish Health and Medicine Authority states that biases of 0.6, 1.7, and 2.8 mmol/mol (0.06, 0.15, 0.25%) increase the number of persons diagnosed with diabetes by 28, 67 and 224%, respectively (22). When this is extended to the 2014 CAP GH2-A results it can be estimated that, if all HbA1c assays in US had been performed with instruments of the manufacturer with the highest positive bias (+4.2 mmol/mol; +0.39%), the prevalence of diabetes would be 600% higher than if all assays had been done with instruments of the manufacturer with the highest negative bias (-2.3 mmol/mol; -0.21%). This is a reason to set very tight criteria, or at least to define workable criteria to facilitate quality improvement. But one should also take into account that diagnosis of diabetes, and changes in therapy should not be based on a single HbA1c result. A second or third sample dramatically reduces the impact of analytical quality on interpretation, most evident in imprecision and to a lesser degree in bias (23). Reason, perhaps, to set more relaxed quality criteria. Some organizations have already set quality targets. From current Danish quality requirements, a maximum CV  of 2.8% (1.8%) and a maximum bias of 2.8% (1.8%) a TAE of 4.2 mmol/mol (0.39%) can be derived (21). The CAP acceptance limit of 6% is 4.3 mmol/mol (0.40%) at an HbA1c concentration of 50 mmol/mol (6.7%) (18): these criteria are close to the chosen TAE of 5 mmol/mol (0.46%) in this paper. The models in this paper can be used to set quality targets for individual labs. But also to set (desirable) quality goals between laboratories within methods (performance of users of a manufacturer) or between laboratories between methods (overall performance of all labs).
Taking into account these considerations, as well as the state of the art, TF- HbA1c suggests to initially set a TAE of 5 mmol/mol (0.46%) with a sigma of 2 for routine laboratories and a sigma of 4 for laboratories performing clinical trials where optimal accuracy and precision is a requirement. But as stated above: this is the starting point for discussion with stakeholders in the field of diabetes and of a drive towards improved quality rather than the final destination or level of quality.

Application
As demonstrated by the examples in this paper the model is suitable to estimate the quality status of HbA1c of a) a single laboratory, b) a single manufacturer, and c) a country. The model also allows comparison over time of analytical performances of manufacturers, which is helpful to select a method or to evaluate whether poor performance in a single laboratory is traceable to either poor operation in that laboratory or to the method used. For valid and fair conclusions it is important to confirm commutability and value assignment with the IFCC Reference Measurement Procedure of the samples in the EQA/PT program from which bias and imprecision data are taken to calculate TE.
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Table 2. Mathematics for both BV and SM models

Total Error 
	1. TE = |B| + 2I
Biological Variationa
	2. TAE = 1.65(f1 x CVI) + f2 						CVI =   2.77% 	(NGSP 1.9%)						CVG = 8.32% 	(NGSP 5.7%)
	Classification	f1	f2	TAE at HbA1c = 50 mmol/mol (6.7%)







Conversion Factors  NGSP from IFCC
		4. HbA1c in Concentration Units: 		NGSP = 0.0915IFCC + 2.15	5. Absolute Bias in Concentrations Units: 	NGSP = 0.0915IFCC	6. Imprecision in CV% at 50 mmol/mol: 		NGSP = 0.685IFCC	7. Imprecision in CV% in NGSP units:		IFCC   = 1.46 NGSP
Symbols	
		TE 	= Total Error			in concentration units	TAE	= Total Allowable Error		in concentration units	|B| 	= Absolute Bias			in concentration units	I	= Imprecision 			in concentration units	CVI	= Intra Individual Variation	in CV%	CVG	= Inter Individual Variation	in CV%	σ	= Chance Failure		in sigma units	f1	= Factor to classify the imprecision component of TAE	f2	= Factor to classify the bias component of TAE

a CVI and CVG taken from the Ricos tables in NGSP units and converted to IFCC with equation 7














Fig. 1. Quality Target Models.
Imprecision in %CV  on the x-axis and bias in mmol/mol (IFCC) and % (NGSP) on the y-axis. Quality Targets are shown in colors for the Biological Variation model (A; optimum, desirable, minimum). And with lines for the Sigma-metrics model (B; 2 – 6 σ). Figure 1C combines both models.The red heart represents the performance of a laboratory with a bias of 1 mmol/mol (0.9%), an imprecision of 1.5% (1.0%) and a TE of 2.5 mmol/mol (0.23%) and meets the “minimum” performance criterion in the Biological Variation model and the “5σ” criterion in the Sigma-metrics model. Fig. 1D shows the impact of varying the set TAE and acceptable σ value on performance.

Fig. 2. Models applied to 26 manufacturer/instrument means in CAP 2014 GH2-A survey.
The mean within manufacturer interlaboratory CV is on the X-axis; the mean manufacturer absolute bias is on the Y-axis. The black star represents the overall mean of all Laboratories. The dots (laboratory instruments) and squares (POCT instruments) represent specific manufacturers with colors for analytical principles: Immunoassays (green), Ion Exchange HPLC (red), Affinity HPLC (yellow), Capillary Electrophoresis (blue) and Dry Chemistry (grey). Abbott Architect c System (A), Abbott Architect I System (B), Axis-Shield Afinion (C), Beckman AU systems (D), Beckman UniCel DxC Synchron (E), Bio-Rad D10 (F), Bio-Rad Variant II (G), Bio-Rad Variant II Turbo (H), Bio-Rad Variant Turbo 2.0 (I), Roche Cobas c311 (J), Roche Cobas c500 series (K), Roche Cobas Integra 400 (L), Roche Cobas Integra 800 (M), Sebia Capillarys 2 Flex Piercing (N), Siemens Advia Chemistry Systems (O), Siemens DCA 2000/2000+ (P), Siemens DCA Vantage (Q), Siemens Dimension ExL (R), Siemens Dimension RxL (S), Siemens Dimension Vista (T), Siemens Dimension Xpand (U), Tosoh G7 Auto HPLC (V), Tosoh G8 Auto HPLC (W), Trinity Biotech HPLC (X), Trinity Biotech Premier Hb9210 (Y), Ortho Clin Diag Vitros 5,1 FS, 4600, 5600 Chem System (Z). For more details see Table 1, supplemental data.

Fig. 3. Models applied to 342 individual laboratories.
Each dot represents an individual laboratory: HPLC (red), Immunoassay (green), Affinity Chromatography (yellow), Capillary Electrophoresis (blue). For reasons of simplicity only 2, 4 and 6σ limits for TAE = 5 mmol/mol (0.46%) of the Sigma-metrics model are shown. Yellow, grey and amber are the limits of optimum, desirable and minimum performance of the biological variation model. Data from the shared 2013 EQA program in Belgium, the Netherlands, Greece and Finland.
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